Iradimed Enterprise Value Multiple from 2010 to 2024

IRMD Stock  USD 42.47  0.35  0.83%   
Iradimed's Enterprise Value Multiple is increasing over the years with very volatile fluctuation. Overall, Enterprise Value Multiple is expected to go to 51.10 this year. During the period from 2010 to 2024 Iradimed Enterprise Value Multiple annual values regression line had geometric mean of  41.09 and mean square error of  9,233. View All Fundamentals
 
Enterprise Value Multiple  
First Reported
2010-12-31
Previous Quarter
26.46758881
Current Value
51.1
Quarterly Volatility
93.03234653
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Iradimed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iradimed main balance sheet or income statement drivers, such as Interest Expense of 702.6 K, Selling General Administrative of 9.3 M or Selling And Marketing Expenses of 7.8 M, as well as many exotic indicators such as Price To Sales Ratio of 9.61, Dividend Yield of 0.0316 or PTB Ratio of 10.29. Iradimed financial statements analysis is a perfect complement when working with Iradimed Valuation or Volatility modules.
  
This module can also supplement various Iradimed Technical models . Check out the analysis of Iradimed Correlation against competitors.

Latest Iradimed's Enterprise Value Multiple Growth Pattern

Below is the plot of the Enterprise Value Multiple of Iradimed Co over the last few years. It is Iradimed's Enterprise Value Multiple historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iradimed's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Multiple10 Years Trend
Very volatile
   Enterprise Value Multiple   
       Timeline  

Iradimed Enterprise Value Multiple Regression Statistics

Arithmetic Mean63.39
Geometric Mean41.09
Coefficient Of Variation146.76
Mean Deviation45.24
Median37.73
Standard Deviation93.03
Sample Variance8,655
Range384
R-Value0.1
Mean Square Error9,233
R-Squared0.01
Significance0.73
Slope2.02
Total Sum of Squares121,170

Iradimed Enterprise Value Multiple History

2024 51.1
2023 26.47
2022 19.17
2021 45.53
2020 393.08
2019 22.57
2018 37.73

About Iradimed Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Iradimed income statement, its balance sheet, and the statement of cash flows. Iradimed investors use historical funamental indicators, such as Iradimed's Enterprise Value Multiple, to determine how well the company is positioned to perform in the future. Although Iradimed investors may use each financial statement separately, they are all related. The changes in Iradimed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Iradimed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Iradimed Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Iradimed. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Multiple 26.47  51.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:
Check out the analysis of Iradimed Correlation against competitors.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Iradimed Stock analysis

When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Valuation
Check real value of public entities based on technical and fundamental data
Commodity Directory
Find actively traded commodities issued by global exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.185
Dividend Share
0.15
Earnings Share
1.4
Revenue Per Share
5.363
Quarterly Revenue Growth
0.137
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.